Open science 鈥� reflecting upon real-world impact
To support听, Pfizer commissioned听听to record a series of podcast interviews with experts working within clinical and medical disciplines. The objective was to share perspectives on the real-world impact and benefit of open science for patients and key stakeholders.
Open science can be best defined as the practice of freely sharing clinical and scientific knowledge in a way that allows others to collaborate and build upon that knowledge to accelerate research applications. Within this open science ecosystem, clinical data sharing and data transparency continue to advance. Many national and international organizations, such as the听听and the UK鈥檚听, are adopting open data policies.
The premise of open science is that research will progress faster if data and knowledge are openly shared, with the caveat of proper safety measures and ethical frameworks. This has been most evident during the ongoing COVID-19 pandemic. But despite significant progress, open science principles and practices still need to be more formally embedded within clinical research institutions and organizations.
The following five podcasts, hosted by Martin Delahunty, are presented:
Joseph Ross 鈥� Open Science and data sharing in clinical research
听is Professor of Medicine and of Public Health at the听. He co-directs the听听in Regulatory Science and Innovation, the听, the听, and leads efforts at Yale New Haven Health System in collaboration with the听. Dr Ross is also currently the US Outreach and Research Editor at the听.
Lonni Besan莽on 鈥� Open science saves lives: lessons from the COVID-19 pandemic
听is a Postdoctoral Research Fellow and Computer Science Engineer at听. His main focus lies on the intersection between human鈥揷omputer interaction and interactive scientific visualization.
Joana Os贸rio 鈥� Open Pharma: driving positive change in the communication of pharma-sponsored research
听is a Communications Consultant at Oxford PharmaGenesis, working on patient engagement projects and Open Pharma, a collaboration that aims to increase transparency and access to pharma-sponsored research outputs.
Akhil Bansal 鈥� Open access and global health inequity: a clinical perspective
听is a medical doctor and a Policy and Research Analyst at听, a social venture capital that incubates and creates strategies for non-governmental organizations (NGOs) working in the global health and health policy sectors. Most of the company鈥檚 work is in low-income countries, where access to scientific and health information is a problem. It is working on incubating NGOs that seek to promote open development and access to science, especially in Sub-Saharan Africa. Dr Bansal was previously a Medical Writer at Oxford PharmaGenesis.
Guy Rouleau 鈥� Open Science to accelerate discovery and deliver cures: a research hospital鈥檚 perspective
Dr Rouleau听is Director of the听Montreal Neurological Institute-Hospital听(The Neuro), Chair of the听Department of Neurology and Neurosurgery of 不良研究所听and Director of the听Department of Neuroscience of 不良研究所 Health Center. As co鈥恌ounder of the听Tanenbaum Open Science Institute, he is pioneering a new way of doing research by transforming The Neuro into the first academic institution to adopt open science principles to accelerate discovery and benefit patients and society.
Disclosure: Inspiring STEM Consulting Limited received funding from Pfizer. None of the podcast participants received funding or were contracted to speak. This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International (CC BY-SA 4.0) licence听
Article by听听| January 25, 2022 at 10:02 am听
听
